vs
ABVC BIOPHARMA, INC.（ABVC）与爱齐科技（ALGN）财务数据对比。点击上方公司名可切换其他公司
爱齐科技的季度营收约是ABVC BIOPHARMA, INC.的1316.1倍（$1.0B vs $796.0K）。爱齐科技净利率更高（13.0% vs -256.6%，领先269.6%）。ABVC BIOPHARMA, INC.同比增速更快（104.5% vs 5.3%）。过去两年ABVC BIOPHARMA, INC.的营收复合增速更高（1041.5% vs 2.5%）
ABVC生物制药是一家处于临床阶段的生物制药企业，专注于开发肿瘤、眼科、中枢神经系统疾病等领域的创新治疗方案，业务覆盖北美及亚洲主要市场，多款自研候选药物正处于临床试验推进阶段。
爱齐科技是一家全球知名医疗设备企业，主营设计、生产及销售隐适美透明矫治器、iTero口内扫描仪及配套服务，客户覆盖正畸医师、全科牙医，面向修复、美容牙科领域，业务分为透明矫治器、扫描仪及服务两大板块，可满足青少年等不同群体的正畸需求
ABVC vs ALGN — 直观对比
营收规模更大
ALGN
是对方的1316.1倍
$796.0K
营收增速更快
ABVC
高出99.2%
5.3%
净利率更高
ALGN
高出269.6%
-256.6%
两年增速更快
ABVC
近两年复合增速
2.5%
损益表 — Q3 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $796.0K | $1.0B |
| 净利润 | $-2.0M | $135.8M |
| 毛利率 | 100.0% | 65.3% |
| 营业利润率 | -246.8% | 14.8% |
| 净利率 | -256.6% | 13.0% |
| 营收同比 | 104.5% | 5.3% |
| 净利润同比 | -417.4% | 30.8% |
| 每股收益（稀释后） | $-0.09 | $1.88 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABVCALGN
| Q4 25 | — | $1.0B | ||
| Q3 25 | $796.0K | $995.7M | ||
| Q2 25 | — | $1.0B | ||
| Q1 25 | — | $979.3M | ||
| Q4 24 | $2.0K | $995.2M | ||
| Q3 24 | $389.3K | $977.9M | ||
| Q2 24 | $117.1K | $1.0B | ||
| Q1 24 | $1.2K | $997.4M |
净利润ABVCALGN
| Q4 25 | — | $135.8M | ||
| Q3 25 | $-2.0M | $56.8M | ||
| Q2 25 | — | $124.6M | ||
| Q1 25 | — | $93.2M | ||
| Q4 24 | $-731.6K | $103.8M | ||
| Q3 24 | $-394.8K | $116.0M | ||
| Q2 24 | $-942.3K | $96.6M | ||
| Q1 24 | $-2.8M | $105.0M |
毛利率ABVCALGN
| Q4 25 | — | 65.3% | ||
| Q3 25 | 100.0% | 64.2% | ||
| Q2 25 | — | 69.9% | ||
| Q1 25 | — | 69.5% | ||
| Q4 24 | 100.0% | 70.0% | ||
| Q3 24 | 99.9% | 69.7% | ||
| Q2 24 | 99.8% | 70.3% | ||
| Q1 24 | 77.0% | 70.0% |
营业利润率ABVCALGN
| Q4 25 | — | 14.8% | ||
| Q3 25 | -246.8% | 9.7% | ||
| Q2 25 | — | 16.1% | ||
| Q1 25 | — | 13.4% | ||
| Q4 24 | -35837.4% | 14.5% | ||
| Q3 24 | -77.7% | 16.6% | ||
| Q2 24 | -734.2% | 14.3% | ||
| Q1 24 | -235539.8% | 15.5% |
净利率ABVCALGN
| Q4 25 | — | 13.0% | ||
| Q3 25 | -256.6% | 5.7% | ||
| Q2 25 | — | 12.3% | ||
| Q1 25 | — | 9.5% | ||
| Q4 24 | -37211.3% | 10.4% | ||
| Q3 24 | -101.4% | 11.9% | ||
| Q2 24 | -804.4% | 9.4% | ||
| Q1 24 | -235203.2% | 10.5% |
每股收益（稀释后）ABVCALGN
| Q4 25 | — | $1.88 | ||
| Q3 25 | $-0.09 | $0.78 | ||
| Q2 25 | — | $1.72 | ||
| Q1 25 | — | $1.27 | ||
| Q4 24 | $-0.02 | $1.40 | ||
| Q3 24 | $-0.03 | $1.55 | ||
| Q2 24 | $-0.08 | $1.28 | ||
| Q1 24 | $-0.29 | $1.39 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $257.2K | $1.1B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.1M | $4.0B |
| 总资产 | $21.2M | $6.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABVCALGN
| Q4 25 | — | $1.1B | ||
| Q3 25 | $257.2K | $1.0B | ||
| Q2 25 | — | $901.2M | ||
| Q1 25 | — | $873.0M | ||
| Q4 24 | $313.1K | $1.0B | ||
| Q3 24 | $208.2K | $1.0B | ||
| Q2 24 | $200.0K | $761.4M | ||
| Q1 24 | $106.4K | $865.8M |
股东权益ABVCALGN
| Q4 25 | — | $4.0B | ||
| Q3 25 | $12.1M | $4.0B | ||
| Q2 25 | — | $3.9B | ||
| Q1 25 | — | $3.8B | ||
| Q4 24 | $1.2M | $3.9B | ||
| Q3 24 | $1.6M | $3.9B | ||
| Q2 24 | $1.8M | $3.8B | ||
| Q1 24 | $1.7M | $3.8B |
总资产ABVCALGN
| Q4 25 | — | $6.2B | ||
| Q3 25 | $21.2M | $6.2B | ||
| Q2 25 | — | $6.2B | ||
| Q1 25 | — | $6.1B | ||
| Q4 24 | $7.5M | $6.2B | ||
| Q3 24 | $7.8M | $6.4B | ||
| Q2 24 | $8.0M | $6.2B | ||
| Q1 24 | $8.0M | $6.2B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-964.7K | $223.2M |
| 自由现金流经营现金流 - 资本支出 | — | $187.3M |
| 自由现金流率自由现金流/营收 | — | 17.9% |
| 资本支出强度资本支出/营收 | — | 3.4% |
| 现金转化率经营现金流/净利润 | — | 1.64× |
| 过去12个月自由现金流最近4个季度 | — | $490.8M |
8季度趋势，按日历期对齐
经营现金流ABVCALGN
| Q4 25 | — | $223.2M | ||
| Q3 25 | $-964.7K | $188.7M | ||
| Q2 25 | — | $128.7M | ||
| Q1 25 | — | $52.7M | ||
| Q4 24 | $-702.1K | $286.1M | ||
| Q3 24 | $60.2K | $263.7M | ||
| Q2 24 | $-211.4K | $159.8M | ||
| Q1 24 | $-955.8K | $28.7M |
自由现金流ABVCALGN
| Q4 25 | — | $187.3M | ||
| Q3 25 | — | $169.0M | ||
| Q2 25 | — | $107.2M | ||
| Q1 25 | — | $27.4M | ||
| Q4 24 | — | $263.1M | ||
| Q3 24 | — | $233.9M | ||
| Q2 24 | — | $106.4M | ||
| Q1 24 | — | $19.3M |
自由现金流率ABVCALGN
| Q4 25 | — | 17.9% | ||
| Q3 25 | — | 17.0% | ||
| Q2 25 | — | 10.6% | ||
| Q1 25 | — | 2.8% | ||
| Q4 24 | — | 26.4% | ||
| Q3 24 | — | 23.9% | ||
| Q2 24 | — | 10.3% | ||
| Q1 24 | — | 1.9% |
资本支出强度ABVCALGN
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 2.0% | ||
| Q2 25 | — | 2.1% | ||
| Q1 25 | — | 2.6% | ||
| Q4 24 | — | 2.3% | ||
| Q3 24 | — | 3.0% | ||
| Q2 24 | — | 5.2% | ||
| Q1 24 | — | 0.9% |
现金转化率ABVCALGN
| Q4 25 | — | 1.64× | ||
| Q3 25 | — | 3.33× | ||
| Q2 25 | — | 1.03× | ||
| Q1 25 | — | 0.57× | ||
| Q4 24 | — | 2.76× | ||
| Q3 24 | — | 2.27× | ||
| Q2 24 | — | 1.66× | ||
| Q1 24 | — | 0.27× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
